Table 2.
Reported availability of treatments to >60% of patients after TIA or stroke, according to tertile of national income.
| GDP per capita |
All respondentsn (%) | |||||
|---|---|---|---|---|---|---|
| N | Lower tertile n (%) | Mid-tertile n (%) | Upper tertile n (%) | p value | ||
| Initial treatment includes | ||||||
| BP-lowering | 46 | 16 (100) | 14 (93) | 10 (67) | 40 (87) | 0.015 |
| Statin | 46 | 9 (56) | 11 (73) | 14 (93) | 34 (74) | 0.06 |
| Antiplatelet | 46 | 15 (94) | 15 (100) | 14 (93) | 44 (96) | 0.60 |
| Carotid intervention | ||||||
| <48 hours | 36 | 0 (0) | 1 (7) | 1 (9) | 2 (6) | 0.61 |
| <1 week | 37 | 0 (0) | 1 (7) | 2 (17) | 3 (8) | 0.34 |
| <2 weeks | 39 | 0 (0) | 1 (8) | 5 (33) | 6 (15) | 0.043 |
| <1 month | 34 | 1 (9) | 2 (15) | 2 (20) | 5 (15) | 0.78 |
| >1 month | 33 | 5 (42) | 0 (0) | 0 (0) | 5 (15) | 0.006 |
| Treatment at one year | ||||||
| BP measured | 42 | 11 (69) | 14 (100) | 8 (67) | 33 (79) | 0.06 |
| BP controlled | 43 | 8 (50) | 9 (64) | 7 (54) | 24 (56) | 0.72 |
| Lipids tested | 42 | 6 (38) | 12 (86) | 6 (50) | 24 (57) | 0.024 |
| Statin | 43 | 7 (44) | 8 (57) | 8 (62) | 23 (53) | 0.60 |
| Antiplatelet | 43 | 14 (88) | 14 (100) | 11 (85) | 39 (91) | 0.33 |
| Anticoagulant | 42 | 7 (44) | 10 (71) | 7 (58) | 24 (57) | 0.31 |
| DOAC | 40 | 2 (13) | 2 (14) | 4 (36) | 8 (20) | 0.28 |
| Follow-up method | ||||||
| Hospital | 43 | 5 (36) | 5 (36) | 4 (27) | 14 (33) | 0.83 |
| Specialist clinic | 39 | 1 (8) | 2 (17) | 1 (7) | 4 (10) | 0.68 |
| Primary care | 43 | 5 (36) | 7 (50) | 10 (67) | 22 (51) | 0.25 |
| No follow-up | 37 | 2 (17) | 0 (0) | 0 (0) | 2 (5) | 0.11 |
Groups are compared by chi-squared tests.
N: number of responses to the question; GDP: gross domestic product; BP: blood pressure; TTE: transthoracic echocardiography; TEE: transoesophageal echocardiography; TCD: transcranial ultrasound.